// App-Quantinova.ai

e19369 : A cost-utility analysis of apalutamide for the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC).

Researchers

Presenter

  • Ambika Parmar

Principal Investigators

  • Narhari Timilshina

  • Urban Emmenegger

  • Shabbir M.H. Alibhai

  • Martin Smoragiewicz

  • Beate Sander

  • Kelvin K. Chan

Medical Centers

  • Sunnybrook Health Sciences Centre, Odette Cancer Centre, University of Toronto, Toronto, ON, Canada

  • Universtiy Health Network, Toronto, ON, Canada

  • Sunnybrook Research Institute, Toronto, ON, Canada

  • Princess Margaret Cancer Centre University Health Network, Toronto, Ontario, Canada

  • Canadian Cancer Trials Group, Kingston, ON, Canada

  • Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON, Canada

Locations

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Nephrology

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved